Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest

被引:53
作者
Simoneau, M [1 ]
LaRue, H [1 ]
Aboulkassim, TO [1 ]
Meyer, F [1 ]
Moore, L [1 ]
Fradet, Y [1 ]
机构
[1] Univ Laval, Ctr Hosp Univ Quebec, Ctr Rech Cancerol, Quebec City, PQ, Canada
关键词
bladder cancer; LOH; recurrence; prognostic; chromosome; 9;
D O I
10.1038/sj.onc.1204022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological significance of chromosome 9 deletions in superficial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P = 0.022). Female patients had more chromosome 9q LOH than male patients did (P = 0.010), Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred significantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions confirmed the correlation (P = 0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of superficial bladder cancer.
引用
收藏
页码:6317 / 6323
页数:7
相关论文
共 36 条
[1]  
Allard P, 1998, BRIT J UROL, V81, P692
[2]  
Allard P, 1995, CLIN CANCER RES, V1, P1195
[3]   Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? [J].
Bartlett, JMS ;
Watters, AD ;
Ballantyne, SA ;
Going, JJ ;
Grigor, KM ;
Cooke, TG .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2193-2198
[4]  
Bartlett JMS, 1997, ANN HUM GENET, V61, P207
[5]  
Clayton D., 1993, STAT MODELS EPIDEMIO
[6]   Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer [J].
Czerniak, B ;
Chaturvedi, V ;
Li, L ;
Hodges, S ;
Johnston, D ;
Ro, JY ;
Luthra, R ;
Logothetis, C ;
Von Eschenbach, AC ;
Grossman, HB ;
Benedict, WF ;
Batsakis, JG .
ONCOGENE, 1999, 18 (05) :1185-1196
[7]   GENETIC ALTERATIONS IN BLADDER-CANCER [J].
DALBAGNI, G ;
PRESTI, J ;
REUTER, V ;
FAIR, WR ;
CORDONCARDO, C .
LANCET, 1993, 342 (8869) :469-471
[8]  
Erbersdobler A, 1998, ONCOL RES, V10, P415
[9]   The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas [J].
Gailani, MR ;
StahleBackdahl, M ;
Leffell, DJ ;
Glynn, M ;
Zaphiropoulos, PG ;
Pressman, C ;
Unden, AB ;
Dean, M ;
Brash, DE ;
Bale, AE ;
Toftgard, R .
NATURE GENETICS, 1996, 14 (01) :78-81
[10]  
HABUCHI T, 1995, ONCOGENE, V11, P1671